Genetic-based dosing in orthopedic patients beginning warfarin therapy. - Wikidata - awgldk - TriplyDB

Genetic-based dosing in orthopedic patients beginning warfarin therapy.

Genetic-based dosing in orthopedic patients beginning warfarin therapy.

http://www.wikidata.org/entity/Q35989429

about

Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response Clopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice?Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis Pharmacogenetics-based warfarin dosing in children Warfarin pharmacogenetics: does more accurate dosing benefit patients?A national clinical decision support infrastructure to enable the widespread and consistent practice of genomic and personalized medicine Effect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarin Warfarin Pharmacogenetics: New Life for an Old Drug A New Pharmacogenetic Algorithm to Predict the Most Appropriate Dosage of Acenocoumarol for Stable Anticoagulation in a Mixed Spanish Population An acenocoumarol dosing algorithm using clinical and pharmacogenetic data in Spanish patients with thromboembolic disease.Estimation of the warfarin dose with clinical and pharmacogenetic data.10 years of oral anticoagulant pharmacogenomics: what difference will it make? A critical appraisal.Integration of genetic, clinical, and INR data to refine warfarin dosing.Warfarin therapy: in need of improvement after all these years.Validation and comparison of pharmacogenetics-based warfarin dosing algorithms for application of pharmacogenetic testing Pharmacogenetics of warfarin: challenges and opportunities.Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients.Genotype-based dosing algorithms for warfarin therapy: data review and recommendations.Pharmacogenetics of anticoagulants.CYP4F2 genetic variant alters required warfarin dose Genetic determinants of response to warfarin during initial anticoagulation Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9.Genotype and risk of major bleeding during warfarin treatment.Interactive modeling for ongoing utility of pharmacogenetic diagnostic testing: application for warfarin therapy.Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): rationale and study design.Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study.The future of warfarin pharmacogenetics in under-represented minority groups.Efficiency and effectiveness of the use of an acenocoumarol pharmacogenetic dosing algorithm versus usual care in patients with venous thromboembolic disease initiating oral anticoagulation: study protocol for a randomized controlled trial Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy.A rapid-ACCE review of CYP2C9 and VKORC1 alleles testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding.Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin.Should we test for CYP2C9 before initiating anticoagulant therapy in patients with atrial fibrillation?Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarin Validation of clinical testing for warfarin sensitivity: comparison of CYP2C9-VKORC1 genotyping assays and warfarin-dosing algorithms.Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin VKORC1 variant genotypes influence warfarin response in patients undergoing total joint arthroplasty: a pilot study The critical path of warfarin dosing: finding an optimal dosing strategy using pharmacogenetics.Ethnic differences in cardiovascular drug response: potential contribution of pharmacogenetics A regulatory science perspective on warfarin therapy: a pharmacogenetic opportunity.

P2860

Q24632568-47FDEB97-C10D-4E87-846E-784158DBE95B Q26823542-356E148A-D297-4B17-8620-A8DE0399C230 Q27002899-9BD5C405-D124-4CAB-92C3-48864C7CC687 Q27008320-1B171017-4526-4D36-9BFE-7CE759C614AE Q27027304-2042026D-D838-49C8-8532-6C1CD0D5B7E4 Q27497190-B0C63BAB-0A6D-4A2B-8094-C88C802BC90F Q28276514-E77AD754-B7F9-4F3E-AF10-4F64160DC4AE Q28468726-240B066A-F364-4810-87A2-CBF27A972635 Q28550740-7D6225E9-72C6-4000-AD7B-386778D7E52D Q30558676-0C18A37B-6611-4973-B4DF-9E5EDC9745A0 Q33410725-FAD0F319-EBD7-42C9-9D90-5CA5DD863BA0 Q33517162-542A7314-2158-41A3-82AA-0F1C8D40E28F Q33550741-9CAA82FA-39C9-4DC3-B0BF-03DE59B7969D Q33793086-D00D4588-B7F0-4326-B611-14097A4BD53B Q33813830-8BF1F34F-CCCE-4435-9042-F45F647ED698 Q33819050-B1DA8ABD-3AFB-4611-95B7-77E0DF80F350 Q34061511-CE8C6E4B-DF3A-4EB1-BAD1-B00475074AD9 Q34065133-DA769BF0-A877-4BF3-8305-E42FD747AEAD Q34219746-9E994957-D06B-4090-B330-A6B428F4E74D Q34746151-0812741F-F9D6-445E-8678-8BDA147B55A2 Q34759038-063817EE-AFC3-4D29-97BA-57B822D2EAE6 Q34994877-7FE16852-B7A4-401D-8422-2D6808DE7C4E Q35006973-E78DA667-D371-4600-8CA5-F56F92FE0D82 Q35092508-326BB558-9788-4636-B344-BF2CFB5B350C Q35218128-6F233376-3073-48E5-940B-4D5FCC76CB70 Q35900767-38E5404F-D806-42DA-B4D8-88F34310F3F7 Q36294461-B0D822E0-9489-4248-A414-A548A1073C23 Q36527206-3B276F3A-650B-4060-AD61-26E80B84BF56 Q37031513-19C6A053-BAC3-48D5-A8E0-22E614D2A6B9 Q37087333-9027AF17-6306-44DB-A9D5-D415ADB4F53B Q37087348-DFDF31D0-BC87-4224-B170-09070C185505 Q37160370-4EACAF75-DB04-4839-8378-A75723CD4EA2 Q37160420-085BDDAA-3991-4EC6-B830-7043B7E81A6D Q37164469-E1B7F25B-6796-4346-92FE-E084B1FA2327 Q37169126-6E281342-5A6E-4E0B-8B18-A1402E9306D4 Q37196787-CF15DFB0-258F-4859-B4CB-72C01A21B38F Q37213180-F8B63D52-37A5-41B6-89DC-657A7278689E Q37247571-DFE4F8E2-CF47-43CC-8288-21BB220968E4 Q37276490-DA168840-D8AD-463A-A714-42610A1E4ADB Q37380399-637B883B-1049-4A5F-A9E2-635F15F48CA2

P2860

Genetic-based dosing in orthopedic patients beginning warfarin therapy.

http://www.wikidata.org/entity/Q35989429

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh

2007年學術文章

@zh-hant

name

Genetic-based dosing in orthopedic patients beginning warfarin therapy.

@ast

Genetic-based dosing in orthopedic patients beginning warfarin therapy.

@en

type

label

Genetic-based dosing in orthopedic patients beginning warfarin therapy.

@ast

Genetic-based dosing in orthopedic patients beginning warfarin therapy.

@en

prefLabel

Genetic-based dosing in orthopedic patients beginning warfarin therapy.

@ast

Genetic-based dosing in orthopedic patients beginning warfarin therapy.

@en

P1433

Q35989429-DCDECF0C-EE7D-400A-9B42-6935C1071079

P1476

Q35989429-D572B31E-4C87-42A3-9030-89279ED01A7C

P2093

Q35989429-18F6FEC8-B67B-4557-B984-5F3188F55F74

Q35989429-18F7271E-92F7-4C0B-8074-3F54CEC3EFE2

Q35989429-23046677-36F9-46C7-BD3C-D79D83513A3C

Q35989429-32B463D8-2953-4A19-99BE-3A2CA9CB3B71

Q35989429-5CED11B4-47D9-40B8-BF1C-F045E035CDDD

Q35989429-78863954-95D1-4B7E-8C37-3E233EB4DFBA

Q35989429-7E9636E7-6203-4095-9DBF-FD1C48527D14

Q35989429-8454ADD3-53F2-4352-9A7C-362FE17B01C3

Q35989429-874B3D5E-C2E2-44EE-A5FE-10D26950CAF0

Q35989429-AF7788D4-EA5C-4959-86BF-F7DFE74576CE

P2860

Q35989429-03B45AF4-3089-4711-9C9C-998438A1F399

Q35989429-041993EF-D8DC-4626-84BC-C1A2925F5A6D

Q35989429-11B16997-46B7-4F17-924A-51A63BCE286A

Q35989429-1FD07036-0E0E-41ED-86AB-E76617EEBAC7

Q35989429-1FE11674-8B16-4F29-8994-7B9F0A7F70F4

Q35989429-29A27898-2D20-44A9-B55D-8964C599212A

Q35989429-32CFE13D-6EB4-464C-B9E4-7A071523F275

Q35989429-3453ACCA-9C2E-439F-82DA-AD8C15465584

Q35989429-3BD4A403-5D37-47FF-9831-F068B185E8E9

Q35989429-501D4B75-B39D-4516-A626-821AB4DF22DB

P304

Q35989429-8A3D9F66-5CD8-4994-B20A-AFEEEBCC7EED

P31

Q35989429-61D7A371-0F8C-49F2-9D5D-35A34BA331EA

P356

Q35989429-F4ACD978-0D69-4119-90A2-E66E549D6C27

P407

Q35989429-B58B0353-7075-45FA-AD6C-97B3D213C969

P433

Q35989429-60992A4B-5C92-4A1A-9365-729B46E0E3C7

P478

Q35989429-073E9F3F-4F5A-4660-9F2B-6C68DD608A98

P50

Q35989429-3B1F88E8-7EAC-4E7A-B2A7-6615B351C2ED

Q35989429-E0F6AF2A-1EFA-4392-A9C2-ABEA8C9A902C

P577

Q35989429-71DEBC7E-B977-4153-BC62-5A8CA104ED16

P5875

Q35989429-23A799A3-B143-4262-B9EE-02BB365EB1B2

P698

Q35989429-6B898A09-B77E-4682-A496-D6C95FC92A41

P932

Q35989429-A572D016-E680-4B47-A0FF-B58FBB4F4030

P356

BLOOD-2007-01-069609

P1433

P1476

Genetic-based dosing in orthopedic patients beginning warfarin therapy

@en

P2093

Amy Tiemeier

http://www.w3.org/2001/XMLSchema#string

Brian F Gage

http://www.w3.org/2001/XMLSchema#string

Charles Eby

http://www.w3.org/2001/XMLSchema#string

Elena Deych

http://www.w3.org/2001/XMLSchema#string

Eric A Millican

http://www.w3.org/2001/XMLSchema#string

Gloria Grice

http://www.w3.org/2001/XMLSchema#string

John C Clohisy

http://www.w3.org/2001/XMLSchema#string

Leonard Grosso

http://www.w3.org/2001/XMLSchema#string

Petra A Lenzini

http://www.w3.org/2001/XMLSchema#string

R Stephen J Burnett

http://www.w3.org/2001/XMLSchema#string

P2860

Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatment of acute venous thromboembolism. A randomized, double-blind, controlled trial.

The influence of age, liver size and enantiomer concentrations on warfarin requirements.

Common VKORC1 and GGCX polymorphisms associated with warfarin dose.

A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity.

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose.

A formula to estimate the approximate surface area if height and weight be known. 1916.

Flexible induction dose regimen for warfarin and prediction of maintenance dose

Association of warfarin dose with genes involved in its action and metabolism.

Review of the rebound phenomenon in new anticoagulant treatments.

Single nucleotide polymorphism genotyping by two colour melting curve analysis using the MGB Eclipse Probe System in challenging sequence environment.

P304

1511-1515

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2007-01-069609

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

110

http://www.w3.org/2001/XMLSchema#string

P50

Paul E. Milligan

P577

2007-03-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6420807

http://www.w3.org/2001/XMLSchema#string

P698

17387222

http://www.w3.org/2001/XMLSchema#string

P932

1975838

http://www.w3.org/2001/XMLSchema#string